Meta analysis of 6 fluvoxamine RCTs showing fluvoxamine associated with lower mortality and hospitalization. 100mg bid showed lower mortality and hospitalization, but 50mg bid did not.Authors use the Hartung-Knapp adjustment and they include trials reporting zero events in both arms - 5 of 6 trials for mortality. This narrows the confidence interval from the Together Trial so that it becomes significant, but this is not logical - zero mortality in both arms does not provide information on the mortality benefit of fluvoxamine.Bias evaluation is not accurate. For example, authors rate the Together Trial as low risk of bias except for some concerns for deviations from the intended interventions. However, this trial not only shows a very high theoretical risk of bias, but also has very high actual bias, randomization failure, blinding failure, and reports conflicting data that is impossible to be correct [Reis].Currently there are 13 fluvoxamine studies and meta analysis shows:

Outcome	Improvement
Mortality	37% lower [-1‑60%]
Ventilation	22% lower [-28‑53%]
Hospitalization	28% lower [-3‑49%]
Cases	28% fewer [18‑37%]